The U.S. Food and Drug Administration (FDA) has approved Darzalex Faspro (daratumumab and hyaluronidase), in combination with Kyprolis (carfilzomib) and the corticosteroid dexamethasone,…
People with blood type O are significantly less likely to develop multiple myeloma, but those who do are…
Xgeva (denosumab) has been approved by the China National Medical Products Administration (NMPA) to prevent…
Administering radiation therapy to people with relapsed or refractory (resistant) multiple myeloma waiting for CAR T-cells to…
Oncopeptides has formally opened sEAPort, its open-label expanded access program allowing adults with…
Janssen‘s new under-the-skin formulation of daratumumab, called Darzalex Faspro, has been recommended for approval…
The long-term survival of people with multiple myeloma following autologous stem cell transplant has steadily improved since 1997…
A new CAR T-cell therapy  for people with multiple myeloma has been successfully created and tested in…
Treatment with belantamab mafodotin, GlaxoSmithKline’s investigational antibody-drug conjugate, resulted in clinically meaningful responses in about one-third of hard-to-treat multiple…
Myeloma Research News brought you daily coverage of important findings, treatment developments, clinical trials, and other events related to multiple myeloma…